Assessment of a panel of miRNAs in serum and pleural fluid for the differential diagnosis of malignant and benign pleural effusion
Cancer Biomarkers · 14.02.2022 · 33 (1) · 71-82
DOI: 10.3233/cbm-210090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, erschienen am 14.02.2022. Verfasst von Li-Rong Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China. Hauptthemen laut MEDLINE: MicroRNAs, Pleural Effusion, Pleural Effusion, Malignant. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Differential diagnosis between malignant pleural effusion (MPE) and benign pleural effusion (BPE) remains a clinical challenge. OBJECTIVE: The aim of the study is to assess the efficacy of the serum and pleural fluid (PF) miRNA panels in distinguishing MPE from BPE. METHODS: Fourteen candidate miRNAs which were shown aberrant expression in lung cancer based on previous studies were tested by quantitative real-time PCR (qRT-PCR) in 20 MPE patients and 20 BPE patients. Significantly aberrantly expressed miRNAs were further assessed by qRT-PCR in all patients enrolled in this study. A receiver operating characteristic (ROC) curve was constructed, and the area under the ROC curve (AUC) was calculated to evaluated the diagnostic performance of the miRNAs. RESULTS: miR-21, miR-29c and miR-182 were found to be significantly aberrantly expressed in the serum and PF of MPE patients. The AUCs for the combination of miR-21, miR-29c and miR-182 in serum and PF were 0.832 and 0.89 respectively in distinguishing MPE from infection-associated PE including tuberculous pleurisy and parapneumonia PE, and 0.866 and 0.919 respectively for differentiating MPE from heart failure-associated PE, which were superior to AUC of each individual miRNAs. CONCLUSIONS: miR-21, miR-29c and miR-182 in serum and PF could be useful biomarkers for diagnosis of MPE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
- Department of Respiratory Disease, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.
- Center of Experimental Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Zitieren
APA
Zhu, L. R., Yuan, R. X., Xia, X. B., Wang, Y., Zhu, Y. M., Fi, L., & Li, J. (2022). Assessment of a panel of miRNAs in serum and pleural fluid for the differential diagnosis of malignant and benign pleural effusion. Cancer Biomarkers, 33(1), 71-82. https://doi.org/10.3233/cbm-210090
Vancouver
Zhu LR, Yuan RX, Xia XB, Wang Y, Zhu YM, Fi L, et al. Assessment of a panel of miRNAs in serum and pleural fluid for the differential diagnosis of malignant and benign pleural effusion. Cancer Biomarkers. 2022;33(1):71-82. doi:10.3233/cbm-210090
BibTeX
@article{Zhu2022,
author = {Zhu, Li-Rong and Yuan, Rong-Xia and Xia, Xian-Bin and Wang, Yi and Zhu, Yu-Min and Fi, Ling and Li, Jian},
title = {Assessment of a panel of miRNAs in serum and pleural fluid for the differential diagnosis of malignant and benign pleural effusion},
journal = {Cancer Biomarkers},
year = {2022},
volume = {33},
number = {1},
pages = {71--82},
doi = {10.3233/cbm-210090}
}
EUVIMED